Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the ...

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...

As more cancers are being linked to the human papillomavirus (HPV), including cancers showing up in younger-than-average patients, a local doctor is promoting the use of the HPV vaccine, which is ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.

Merck blamed the lower than expected forecast on the decision to pause shipments of its Gardasil vaccine to China until at least mid-year. Gardasil is given to patients to prevent human papillomavirus ...

The increase is driven by growth in oncology and cardiovascular, partially offset by declines in diabetes, vaccines ... to temporarily pause Gardasil/Gardasil 9 shipments into China beginning ...

Gardasil is a vaccine that prevents cancer from HPV ... Merck is hoping that Gardasil's expanded approval for men ages 9 to 26 in China will eventually help boost uptake of the shot.

Excluding the impact of foreign exchange, sales increased 9%. Merck reported adjusted ... Merck reported a decline of 17% in sales of Gardasil to $1.55 billion, a vaccine that prevents cancer ...